• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

SCH 56592与氟康唑和伊曲康唑对念珠菌属的活性比较

Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp.

作者信息

Law D, Moore C B, Denning D W

机构信息

Department of Microbiology, Hope Hospital, Salford, United Kingdom.

出版信息

Antimicrob Agents Chemother. 1997 Oct;41(10):2310-1. doi: 10.1128/AAC.41.10.2310.

DOI:10.1128/AAC.41.10.2310
PMID:9333073
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC164118/
Abstract

The in vitro activity of Schering 56592, a new azole drug, was compared with those of fluconazole and itraconazole against 103 isolates of Candida comprising 10 different species. Schering 56592 was more active than itraconazole and fluconazole, and it was active against many fluconazole-resistant isolates.

摘要

将一种新型唑类药物先灵葆雅56592的体外活性与氟康唑和伊曲康唑针对包括10个不同种的103株念珠菌的活性进行了比较。先灵葆雅56592比伊曲康唑和氟康唑活性更强，并且对许多耐氟康唑的菌株都有活性。

相似文献

1
Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp.SCH 56592与氟康唑和伊曲康唑对念珠菌属的活性比较
Antimicrob Agents Chemother. 1997 Oct;41(10):2310-1. doi: 10.1128/AAC.41.10.2310.
2
In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp.UR-9825、伊曲康唑和氟康唑对念珠菌属临床分离株的体外比较活性
J Antimicrob Chemother. 1999 Aug;44(2):283-6. doi: 10.1093/jac/44.2.283.
3
Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain.伏立康唑和伊曲康唑对来自西班牙的念珠菌属氟康唑敏感及氟康唑耐药临床分离株的体外活性比较
Eur J Clin Microbiol Infect Dis. 1999 Jun;18(6):432-5. doi: 10.1007/s100960050313.
4
In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America.BMS-207147对来自北美和拉丁美洲哨兵抗菌监测计划的600多株当代临床念珠菌血流分离株的体外活性。
Antimicrob Agents Chemother. 1999 Sep;43(9):2236-9. doi: 10.1128/AAC.43.9.2236.
5
Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole.伏立康唑对氟康唑敏感和耐药念珠菌分离株的作用：与伊曲康唑和酮康唑相比的体外疗效
J Antimicrob Chemother. 1998 Aug;42(2):253-6. doi: 10.1093/jac/42.2.253.
6
In vitro susceptibility of Candida spp. to fluconazole, itraconazole and voriconazole and the correlation between triazoles susceptibility: Results from a five-year study.念珠菌属对氟康唑、伊曲康唑和伏立康唑的体外敏感性及三唑类药物敏感性的相关性：一项为期五年的研究结果。
J Mycol Med. 2018 Jun;28(2):310-313. doi: 10.1016/j.mycmed.2018.03.005.
7
Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae.一种新型三唑类药物Sch 56592的活性，与其他四种抗真菌药物针对念珠菌属和酿酒酵母临床分离株的活性比较。
Antimicrob Agents Chemother. 1997 Feb;41(2):233-5. doi: 10.1128/AAC.41.2.233.
8
In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans.泊沙康唑（Sch 56592）与伊曲康唑和氟康唑相比，对3685株念珠菌属和新型隐球菌临床分离株的体外活性。
Antimicrob Agents Chemother. 2001 Oct;45(10):2862-4. doi: 10.1128/AAC.45.10.2862-2864.2001.
9
In vitro activities of new and conventional antimycotics against fluconazole-susceptible and non-susceptible Brazilian Candida spp. isolates.新型和传统抗真菌药物对氟康唑敏感及不敏感的巴西念珠菌属分离株的体外活性。
Mycoses. 2006 May;49(3):220-5. doi: 10.1111/j.1439-0507.2006.01226.x.
10
In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.卡泊芬净与氟康唑和伊曲康唑相比，对3959株念珠菌属临床分离株（包括157株氟康唑耐药分离株）的体外活性。
Antimicrob Agents Chemother. 2003 Mar;47(3):1068-71. doi: 10.1128/AAC.47.3.1068-1071.2003.

引用本文的文献

1
Surfactin and Capric Acid Affect the Posaconazole Susceptibility of Strains with Altered Sterols and Sphingolipids Biosynthesis.表面活性剂和癸酸对甾醇和鞘脂类生物合成改变的菌株的泊沙康唑敏感性的影响。
Int J Mol Sci. 2023 Dec 15;24(24):17499. doi: 10.3390/ijms242417499.
2
Mitochondrial Complex I Is a Global Regulator of Secondary Metabolism, Virulence and Azole Sensitivity in Fungi.线粒体复合物I是真菌次级代谢、毒力和唑敏感性的全局调节因子。
PLoS One. 2016 Jul 20;11(7):e0158724. doi: 10.1371/journal.pone.0158724. eCollection 2016.
3
Advances in synthetic approach to and antifungal activity of triazoles.三唑类化合物的合成方法及抗真菌活性研究进展。
Beilstein J Org Chem. 2011;7:668-77. doi: 10.3762/bjoc.7.79. Epub 2011 May 25.
4
In search of the holy grail of antifungal therapy.寻找抗真菌治疗的圣杯。
Trans Am Clin Climatol Assoc. 2008;119:197-215; discussion 215-6.
5
In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.泊沙康唑、氟康唑、伊曲康唑、伏立康唑和两性霉素B对大量临床重要霉菌和酵母菌的体外活性。
Antimicrob Agents Chemother. 2006 Jun;50(6):2009-15. doi: 10.1128/AAC.00163-06.
6
Antifungal drugs and rational use of antifungals in treating invasive aspergillosis: the role of the hospital pharmacist.
Pharm World Sci. 2005 Feb;27(1):31-4. doi: 10.1007/s11096-004-1735-0.
7
Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.泊沙康唑（SCH 56592）治疗和预防实验性侵袭性肺曲霉病的抗真菌活性及药代动力学：与半乳甘露聚糖抗原血症的相关性
Antimicrob Agents Chemother. 2001 Mar;45(3):857-69. doi: 10.1128/AAC.45.3.857-869.2001.
8
In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida.新型三唑类抗真菌药物SCH 56592（泊沙康唑）对曲霉和念珠菌的体外及体内活性
Antimicrob Agents Chemother. 2000 Aug;44(8):2017-22. doi: 10.1128/AAC.44.8.2017-2022.2000.
9
In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens.新型抗真菌三唑类药物SCH 56592对常见及新出现的酵母病原体的体外活性
Antimicrob Agents Chemother. 2000 Jan;44(1):226-9. doi: 10.1128/AAC.44.1.226-229.2000.
10
Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts.三唑衍生物SCH 56592（泊沙康唑）在免疫功能正常和免疫抑制的小鼠宿主中对原生动物寄生虫克氏锥虫（裂体锥虫）耐药菌株的活性。
Antimicrob Agents Chemother. 2000 Jan;44(1):150-5. doi: 10.1128/AAC.44.1.150-155.2000.

本文引用的文献

1
Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae.一种新型三唑类药物Sch 56592的活性，与其他四种抗真菌药物针对念珠菌属和酿酒酵母临床分离株的活性比较。
Antimicrob Agents Chemother. 1997 Feb;41(2):233-5. doi: 10.1128/AAC.41.2.233.
2
In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts.抗真菌三唑类药物SCH56592和伊曲康唑对白色念珠菌、新型隐球菌及其他致病性酵母菌活性的体外研究。
Antimicrob Agents Chemother. 1997 Jan;41(1):180-3. doi: 10.1128/AAC.41.1.180.
3
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.唑类药物SCH56592对新型隐球菌的体外和体内疗效。
Antimicrob Agents Chemother. 1996 Aug;40(8):1910-3. doi: 10.1128/AAC.40.8.1910.
4
Itraconazole susceptibilities of fluconazole susceptible and resistant isolates of five Candida species.
J Antimicrob Chemother. 1995 Nov;36(5):787-93. doi: 10.1093/jac/36.5.787.
5
Improved medium for fluconazole susceptibility testing of Candida albicans.用于白色念珠菌氟康唑药敏试验的改良培养基。
Antimicrob Agents Chemother. 1994 Jan;38(1):45-8. doi: 10.1128/AAC.38.1.45.
6
Fluconazole-resistant candidosis in an HIV cohort.艾滋病病毒感染者队列中的氟康唑耐药念珠菌病
AIDS. 1994 Jun;8(6):787-92. doi: 10.1097/00002030-199406000-00010.
7
Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis.接受长期氟康唑治疗口腔念珠菌病的HIV感染患者中念珠菌属唑类耐药性的出现。
J Antimicrob Chemother. 1995 Jan;35(1):103-14. doi: 10.1093/jac/35.1.103.
8
High prevalence of antifungal resistance in Candida spp. from patients with AIDS.艾滋病患者念珠菌属中抗真菌耐药性的高流行率。
J Antimicrob Chemother. 1994 Nov;34(5):659-68. doi: 10.1093/jac/34.5.659.
9
Can we prevent azole resistance in fungi?我们能预防真菌中的唑类耐药性吗？
Lancet. 1995 Aug 19;346(8973):454-5. doi: 10.1016/s0140-6736(95)91314-9.
10
Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain.西班牙对氟康唑敏感性降低的白色念珠菌的伊曲康唑和咪唑类抗真菌药物的体外活性模式
Antimicrob Agents Chemother. 1995 Jul;39(7):1512-6. doi: 10.1128/AAC.39.7.1512.